<DOC>
	<DOCNO>NCT00087347</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure magnetic resonance imaging ( MRI ) use ferumoxytol may improve ability detect cancer spread lymph node may help plan effective cancer treatment . PURPOSE : This clinical trial study well MRI use ferumoxytol work detect metastasis lymph node patient primary prostate cancer primary breast cancer .</brief_summary>
	<brief_title>Magnetic Resonance Imaging Lymph Nodes Using Ferumoxytol Patients With Primary Prostate Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine range optimal timing magnetic resonance image lymph node administration ferumoxytol , term assess signal intensity use pre-defined pulse sequence region interest visual criterion , patient primary prostate breast cancer schedule undergo surgical lymph node dissection sample . Secondary - Correlate MRI signal intensity histological finding patient undergoing procedure . OUTLINE : This open-label , pilot study . Patients undergo baseline MRI . Within 24 hour baseline MRI , patient receive ferumoxytol IV 10-15 second ( 1 hour ) . Patients undergo MRI immediately ferumoxytol administration ( discretion principal investigator ) 24-28 hour . Patients follow 2 week . PROJECTED ACCRUAL : A total 10-14 patient ( 6-8 prostate cancer 4-6 breast cancer ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary prostate breast cancer Suspected lymph node metastatic disease standard MRI CT scan Scheduled surgical lymph node dissection sample Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic No prior ferritin &gt; 800 ng/mL No prior transferrin saturation &gt; 60 % No history iron overload hemachromatosis Patients clinical history suspect iron overload hemachromatosis must normal serum iron , ferritin , transferrin saturation Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT ≤ 2 time ULN Renal Not specify Other No requirement monitor anesthesia MRI No known allergic hypersensitivity reaction follow parenterallyadministered preparation : Iron Dextran Iron dextran Iron polysaccharide Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>